Inhibition of hepatitis B virus production by Boehmeria nivea root extract in HepG2 2.2.15 cells

被引:39
作者
Huang, Kai-Ling
Lai, Yiu-Kay
Lin, Chih-Chien
Chang, Jia-Ming [1 ]
机构
[1] Dev Ctr Biotechnol, Div Res & Dev, Xizhi City 221, Taipei County, Taiwan
[2] Natl Tsing Hua Univ, Dept Life Sci, Hsinchu 30013, Taiwan
[3] Natl Tsing Hua Univ, Inst Biotechnol, Hsinchu 30013, Taiwan
[4] Da Yeh Univ, Dept Bioresources, Changhua 515, Taiwan
关键词
Boehmeria nivea; medicinal herb; antiviral agent; hepatitis B virus; anti-hepatitis B virus; HepG2; 2.2.15;
D O I
10.3748/wjg.v12.i35.5721
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
AIM: To explore the anti-hepatitis B virus (HBV) effects of Boehmeria nivea (B. nivea) root extract (BNE) by using the HepG2 2.2.15 cell model system. METHODS: Hepatitis B surface antigen (HBsAg), hepatitis B virus e antigen (HBeAg), and HBV DNA were measured by using ELISA and real-time PCR, respectively. Viral DNA replication and RNA expression were determined by using Southern and Northern blot, respectively. RESULTS: In HepG2 2.2.15 cells, HBeAg (60%, P < 0.01) and particle-associated HBV DNA (> 99%, P < 0.01) secretion into supernatant were significantly inhibited by BNE at a dose of 100 mg/L, whereas the HBsAg was not inhibited. With different doses of BNE, the reduced HBeAg was correlated with the inhibition of HBV DNA. The anti-HBV effect of BNE was not caused by its cytotoxicity to cells or inhibition of viral DNA replication and RNA expression. CONCLUSION: BNE could effectively reduce the HBV production and its anti-HBV machinery might differ from the nucleoside analogues. (C) 2006 The WJG Press. All rights reserved.
引用
收藏
页码:5721 / 5725
页数:5
相关论文
共 31 条
[11]  
Dixon JS, 2000, ACTA GASTRO-ENT BELG, V63, P348
[12]   INHIBITION OF THE REPLICATION OF HEPATITIS-B VIRUS INVITRO BY 2',3'-DIDEOXY-3'-THIACYTIDINE AND RELATED ANALOGS [J].
DOONG, SL ;
TSAI, CH ;
SCHINAZI, RF ;
LIOTTA, DC ;
CHENG, YC .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (19) :8495-8499
[13]   Lamivudine resistance in hepatitis B: mechanisms and clinical implications [J].
Fischer, KR ;
Gutfreund, WS ;
Tyrrell, DL .
DRUG RESISTANCE UPDATES, 2001, 4 (02) :118-128
[14]   Virologic response and resistance to adefovir in patients with chronic hepatitis B [J].
Fung, SK ;
Chae, HB ;
Fontana, RJ ;
Conjeevaram, H ;
Marrero, J ;
Oberhelman, K ;
Hussain, M ;
Lok, ASF .
JOURNAL OF HEPATOLOGY, 2006, 44 (02) :283-290
[15]   Mechanisms of disease: Hepatitis B virus infection - Natural history and clinical consequences [J].
Ganem, D ;
Prince, AM .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (11) :1118-1129
[16]   THERAPEUTIC LANDSCAPES - MEDICAL ISSUES IN LIGHT OF THE NEW CULTURAL-GEOGRAPHY [J].
GESLER, WM .
SOCIAL SCIENCE & MEDICINE, 1992, 34 (07) :735-746
[17]  
Huang RL, 1996, HEPATOLOGY, V24, P508, DOI 10.1002/hep.510240307
[18]  
Knipe DM., 2001, Fundamental Virology, V4th ed.
[19]   Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection [J].
Lai, CL ;
Rosmawati, M ;
Lao, J ;
Van Vlierberghe, H ;
Anderson, FH ;
Thomas, N ;
Dehertogh, D .
GASTROENTEROLOGY, 2002, 123 (06) :1831-1838
[20]   Evaluation of the hepatoprotective and antioxidant activity of Boehmeria nivea var. nivea and B-nivea var. tenacissima [J].
Lin, CC ;
Yen, MH ;
Lo, TS ;
Lin, JM .
JOURNAL OF ETHNOPHARMACOLOGY, 1998, 60 (01) :9-17